Welcome to our dedicated page for Bioxcel Therapeutics SEC filings (Ticker: BTAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioXcel Therapeutics filings document regulatory, financing, governance, and operating disclosures for a Nasdaq-listed biopharmaceutical company focused on AI-supported drug re-innovation in neuroscience. The company’s Form 8-K reports include IGALMI regulatory updates, business and financial results, and exhibits tied to press releases and material corporate events.
The filing record also covers registered direct offerings, common stock, pre-funded warrants and accompanying warrants, credit agreement amendments, registration rights, unregistered equity issuances, and retention or milestone-based compensation arrangements. These disclosures describe BioXcel’s capital structure, contractual obligations, Nasdaq-listed common stock, and formal updates connected to its approved IGALMI product and BXCL501 development program.
BioXcel Therapeutics, Inc. reported a new stock option grant to director Sandeep Laumas. On 01/09/2026, he received a stock option for 17,000 shares of common stock at an exercise price of $2.01 per share, expiring on 01/09/2036. The option was granted at no cost to him and is reported as directly owned, with 17,000 derivative securities beneficially owned after the transaction.
The option will vest and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of stockholders after the grant date, provided he continues to serve as a non-employee director through that vesting date.
BioXcel Therapeutics director Rajiv Patni received a grant of 17,000 stock options on January 9, 2026. The options have an exercise price of $2.01 per share and give the right to purchase 17,000 shares of BioXcel Therapeutics common stock.
These options were reported as acquired at a price of $0 for the derivative itself, with 17,000 derivative securities beneficially owned after the transaction, all held directly. The options expire on January 9, 2036 and will vest on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of stockholders, subject to Patni continuing to serve as a non-employee director through that vesting date.
BioXcel Therapeutics, Inc. granted director Peter Mueller a new stock option award. On 01/09/2026, he received an option to buy 17,000 shares of BioXcel common stock at an exercise price of $2.01 per share, expiring on 01/09/2036. The option was granted at a price of $0 for the derivative itself and is held directly by Mueller.
The option will vest and become exercisable on the earlier of the first anniversary of the grant date or the day immediately before the next annual meeting of stockholders after the grant date, as long as Mueller continues to serve as a non-employee director through that vesting date. Following this grant, he beneficially owns 17,000 stock options.
BioXcel Therapeutics director Michal Votruba received a grant of 17,000 stock options on January 9, 2026. These options give the right to purchase 17,000 shares of BioXcel Therapeutics common stock and expire on January 9, 2036. The grant is structured so that the options vest and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of stockholders after the grant date, provided Votruba continues to serve as a non-employee director through that vesting date. After this grant, Votruba beneficially owns 17,000 derivative securities in the form of these options, held directly.
BioXcel Therapeutics director receives stock option grant
BioXcel Therapeutics, Inc. reported that director Michael Patrick Miller received a stock option award for 17,000 shares of common stock on 01/09/2026. The option has an exercise price of $2.01 per share and is held directly.
According to the vesting terms, the option will become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of stockholders after the grant date, provided he continues to serve as a non-employee director through the vesting date. Following this grant, Miller beneficially owns 17,000 stock options.
BioXcel Therapeutics director June Bray reported a grant of 17,000 stock options. The options give her the right to buy 17,000 shares of BioXcel Therapeutics common stock at an exercise price of $2.01 per share, based on a grant dated January 9, 2026. Following this award, she beneficially owns 17,000 derivative securities in the form of these options, held directly.
According to the vesting terms, the option will become exercisable on the earlier of the first anniversary of the grant date or the day immediately before the next annual meeting of stockholders after the grant date, as long as she continues to serve as a non-employee director through that vesting date.
BioXcel Therapeutics director David J. Mack received a grant of 17,000 stock options on January 9, 2026. These options give him the right to buy BioXcel common stock at an exercise price of $2.01 per share. The filing shows this as a direct holding and lists 17,000 derivative securities beneficially owned after the grant. According to the vesting terms, the options will become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of stockholders after the grant, as long as he continues serving as a non-employee director through that vesting date.
BioXcel Therapeutics, Inc. reported that Mark Pavao is joining the company as Interim Chief Commercial Officer, effective around January 12, 2026. His role is to support the potential launch of IGALMI in the at-home setting.
The company plans to submit a supplemental New Drug Application (sNDA) this month seeking FDA approval for IGALMI for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia. The filing also reiterates that these plans are forward-looking and subject to various risks and uncertainties.
BioXcel Therapeutics, Inc. CEO and President Vimal Mehta reported the vesting and settlement of restricted stock units into common stock. On December 14, 2025, 164 RSUs converted into 164 shares of common stock, and on December 15, 2025, 219 RSUs converted into 219 shares. Each RSU represents a contingent right to receive one share of common stock.
After these transactions, Mehta directly beneficially owned 20,876 shares of BioXcel Therapeutics common stock. In addition, 125 shares are held indirectly by his spouse and 480,343 shares are held indirectly by BioXcel LLC, an affiliate where he holds executive and board roles, with beneficial ownership of those securities disclaimed except to the extent of his pecuniary interest.
BioXcel Therapeutics, Inc. reported that its Chief Financial Officer, Richard Steinhart, acquired additional common shares through the vesting and settlement of restricted stock units (RSUs). On 12/14/2025, 33 RSUs converted into 33 shares of common stock, and on 12/15/2025, 35 RSUs converted into 35 shares of common stock, both reported as acquisitions.
Following these transactions, he directly beneficially owned 6,577 shares of BioXcel common stock. The filing notes RSU awards originally granted on March 14, 2022 for 521 RSUs and on March 15, 2023 for 562 RSUs, each vesting 25% on the first anniversary of the grant date and 6.25% at the end of each successive three-month period thereafter, subject to continued employment. After the reported conversions, he continues to hold 130 and 282 RSUs, respectively.